This prepared NPS dispersion was stirred at 300 rpm for 2 h to make sure complete cross-linking of chitosan. The SP nanoparticles (SP-NPS) were made by dissolving spantide II and phosphatidylinositol (PI) in ethanol and blended with organic phase containing PLGA. of KP permeated for KP-SPN or SP+KP-SPN was improved by 9.92 folds than KP-gel. The ear thickness in ACD model as well as the appearance of IL-17 and IL-23; PASI rating and TEWL values in psoriatic plaque like model were significantly less (p<0.001) for SPN compared to control gel. Our results suggest that SP+KP-SPN have significant potential for the percutaneous delivery of SP and KP to the deeper skin layers for treatment of various skin SR 3576 inflammatory disorders. == 1. Introduction == In the last decade, an increasing number of investigations concerning the use of nanoscale structures for drug and gene delivery purpose have been reported. Nanocarriers have been investigated for delivery of drugs to the specific anatomical sites such as brain [1], eyes [2], lungs [3], intestine [4], nose [5] and skin [6] etc. To improve the notoriously low drug absorption from the skin surface, nanoparticulate carriers have proven to be efficient and advantageous. Development of successful topical/transdermal drug delivery systems has been limited in scope due to the significant penetration barrier provided by the stratum corneum (SC) SR 3576 whose composition limits the application of number of suitable drugs for topical and transdermal delivery. However, there is a growing interest in the development of efficient targeted drug delivery systems to physiological sites in the skin [7]. Several attempts have been made and are still under investigation to develop topical formulation of macromolecules for the treatment of various skin diseases. Currently, these diseases are principally treated with topical corticosteroids that target a variety of pathways of the inflammation cascade [8]. However, clinical use of corticosteroid therapy is limited due to associated local side effects such as skin atrophy, telangiectasia, acne and secondary infections as well as SR 3576 contact dermatitis and perioral dermatitis. Spantide II (SP), a neurokinin1 (NK1) receptor antagonist, is a neuropeptide with known anti-inflammatory activity [910]. Combination of anewneuropeptide, SP, along with ketoprofen (KP), a well known potent non-steroidal anti-inflammatory drug (NSAID) [11] in a topical formulation will have great impact for the treatment of skin disorders with minimal adverse effects. In the field of dermatology and cosmetology, micro and nano sized particles have been thoroughly investigated and some formulations are already commercially available. Recently solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC) and lipid nanocapsules have shown improved drug permeation through the skin. However due to their limited drug loading and phase stability issue, their application for clinical use is restricted. Therefore, increased attention has been given to polymeric nanoparticles. Variousnon-toxicand biodegradable synthetic or semi-synthetic polymers, including polylactic acid (PLA) [12], poly(lactic-co-glycolic acid (PLGA) [13], poly(-caprolactone) [14], chitosan [15] have shown promising results for topical drug delivery. These polymeric nanoparticles offer advantages of controlled and sustained release via modification of polymer composition and reducing irritation associated with direct contact of drug with skin. PLGA based nanoparticles have been extensively studied since Mouse monoclonal to CD11b.4AM216 reacts with CD11b, a member of the integrin a chain family with 165 kDa MW. which is expressed on NK cells, monocytes, granulocytes and subsets of T and B cells. It associates with CD18 to form CD11b/CD18 complex.The cellular function of CD11b is on neutrophil and monocyte interactions with stimulated endothelium; Phagocytosis of iC3b or IgG coated particles as a receptor; Chemotaxis and apoptosis they offer number of advantages for skin delivery includingnon-toxicity andbiodegradability, by hydrolysis leading to formation of water and carbon dioxide and entrapment of various therapeutic moieties [16]. Drug delivery into the skin by PLGA nanoparticles can be enhanced by modifying the particle surface with a cationic polymer such as chitosan. Chitosan is a.